BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37609730)

  • 1. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
    Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
    Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
    Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK inhibitor: Introduction.
    Raychaudhuri SP; Raychaudhuri SK
    Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
    Ryguła I; Pikiewicz W; Kaminiów K
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance.
    Raychaudhuri SP; Shah RJ; Banerjee S; Raychaudhuri SK
    Curr Rheumatol Rep; 2024 Jun; 26(6):204-213. PubMed ID: 38492148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK inhibitors and autoimmune rheumatic diseases.
    Benucci M; Bernardini P; Coccia C; De Luca R; Levani J; Economou A; Damiani A; Russo E; Amedei A; Guiducci S; Bartoloni E; Manfredi M; Grossi V; Infantino M; Perricone C
    Autoimmun Rev; 2023 Apr; 22(4):103276. PubMed ID: 36649877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK inhibition in the treatment of inflammatory rheumatic diseases.
    Šenolt L
    Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
    Solimani F; Meier K; Ghoreschi K
    Front Immunol; 2019; 10():2847. PubMed ID: 31849996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
    Alten R; Mischkewitz M; Stefanski AL; Dörner T
    Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
    O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
    Front Immunol; 2021; 12():672461. PubMed ID: 34248953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
    T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
    BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
    Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
    Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis.
    Raychaudhuri SK; Raychaudhuri SP
    Curr Opin Rheumatol; 2017 Jul; 29(4):311-316. PubMed ID: 28394822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
    Cinats A; Heck E; Robertson L
    Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
    J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.